Press Releases

Motif selected to present at Biotech Showcase, San Francisco, January 2016

By December 7, 2015No Comments

Motif Bio plc (AIM: MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, today announced that the Company has been selected to present at the Biotech Showcase 2016, San Francisco, on:

Monday, January 11, 2016 at 14:00 PST

Track: D – Powell (3rd Floor)

Biotech Showcase, which runs alongside the largest healthcare investor event of the year – the JP Morgan Annual Healthcare Conference – is an investor and partnering conference dedicated to providing private and public life sciences companies an opportunity to meet with investors and pharmaceutical executives from around the world.

Graham Lumsden, Chief Executive Officer at Motif, said: “Being selected to present at such an important event is recognition of Motif’s success to date and future potential. Members of the Motif Leadership Team will be in San Francisco to meet pharma and biotech investors and partners attending the Biotech Showcase and JP Morgan conference.”

Enquiries

Motif Bio plc

Graham Lumsden, Chief Executive Officer
David Huang, Chief Medical Officer
info@motifbio.com

Zeus Capital Limited (Nominated Advisor and Broker)

Phil Walker / Dan Bate
Dominic Wilson
+44 (0) 20 3829 5000

Northland Capital Partners (Broker)

Patrick Claridge / David Hignell
John Howes / Mark Treharne (Broking)
+44 (0) 207 382 1100

MC Services AG (Trade PR)

Raimund Gabriel
Shaun Brown
+49 (0) 89 210 2280
+44 (0) 207 148 5998

Plumtree Capital Limited (Financial Advisor)

Stephen Austin
+44 (0) 207 183 2493

Yellow Jersey PR (Financial PR)

Charles Goodwin
Dominic Barretto
+44 (0) 7747 788 221

Notes to Editors

Motif is a clinical-stage biopharmaceutical company, specialising in the development of novel antibiotics that are designed to be effective against serious and life-threatening infections caused by multi-drug resistant bacteria. Our lead product candidate, iclaprim, is being developed for the treatment of the most common and serious bacterial infections such as acute bacterial skin and skin structure infections (ABSSSI) and hospital acquired bacterial pneumonia (HABP), including those caused by resistant strains such as MRSA (methicillin-resistant Staphylococcus aureus).  Two Phase III ABSSSI clinical trials are on track to be completed in 2017 and if approved, iclaprim could be ready for commercialization in 2018. The Company is in discussions with pharmaceutical companies and universities to build a pipeline of innovative antibiotics targeting Gram-positive and Gram-negative bacteria.  For additional information about Motif please visit www.motifbio.com.